Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 255 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CMV Disease Clear all
Completed Not applicable Interventional

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002432
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 3 Interventional

A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes

NCT00002377
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Valganciclovir, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
14 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
15
States / cities
Irvine, California • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jul 24, 2026, 12:46 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

NCT04840199
View directory record Official record
Conditions
HIV Infections, Cytomegalovirus, CMV
Interventions
Letermovir Oral Tablet
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 24, 2026, 12:46 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants

NCT03107871
View directory record Official record
Conditions
Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss
Interventions
Valganciclovir, Simple Syrup
Drug
Lead sponsor
Albert Park
Other
Eligibility
1 Month to 12 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
30
States / cities
Palo Alto, California • San Diego, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 2 Interventional Results available

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

NCT02210065
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

NCT01376804
View directory record Official record
Conditions
Kidney Transplantation, Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
4 Months to 16 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Gainesville, Florida • Los Angeles, Louisiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Not applicable Interventional

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

NCT00002142
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Cidofovir, Probenecid
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study in Adolescent Females to Explore Cytomegalovirus Infection

NCT01691820
View directory record Official record
Conditions
Infections, Cytomegalovirus
Interventions
Blood collection, Urine collection, Saliva collection
Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 17 Years · Female only
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Stevensville, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 3 Interventional

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

NCT00000688
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jul 24, 2026, 12:46 AM EDT
Withdrawn Not applicable Interventional

Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila

NCT07111039
View directory record Official record
Conditions
Gynecologic Cancer, Genitourinary Cancer
Interventions
Airway Pressure Release Ventilation, Conventional Mechanical Ventilation
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

NCT00000981
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Fiacitabine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Jul 24, 2026, 12:46 AM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 12:46 AM EDT
Recruiting No phase listed Observational

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

NCT01011712
View directory record Official record
Conditions
EBV, HSV, VZV, HPV, CMV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Not applicable Interventional

A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir

NCT00002251
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

NCT01570283
View directory record Official record
Conditions
Viral Infection
Interventions
Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Not applicable Interventional Results available

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

NCT02108522
View directory record Official record
Conditions
Infection
Interventions
Multivirus Specific T cells
Biological
Lead sponsor
AlloVir
Industry
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Jul 24, 2026, 12:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction

NCT00001531
View directory record Official record
Conditions
Arterial Occlusive Diseases, Atherosclerosis, Coronary Disease, Cytomegalovirus Infections
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Not applicable Interventional

An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients

NCT00002039
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 12:46 AM EDT
Recruiting Phase 1 Interventional

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

NCT06926894
View directory record Official record
Conditions
Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection, Immune Deficiency
Interventions
Rapidly generated virus specific T (R-MVST) cells
Drug
Lead sponsor
Columbia University
Other
Eligibility
3 Months to 26 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 1 Interventional

A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients

NCT00000768
View directory record Official record
Conditions
Colitis, HIV Infections
Interventions
Glutamic acid hydrochloride, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

NCT05089630
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution)
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
18
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 12:46 AM EDT
Terminated Phase 1 Interventional

Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells

NCT03798301
View directory record Official record
Conditions
CMV Infection, Cytomegalovirus Infections, CMV Viremia, Opportunistic Infections
Interventions
CMV-specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Month and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 24, 2026, 12:46 AM EDT
Completed Phase 2 Interventional

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

NCT00000712
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
8
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 24, 2026, 12:46 AM EDT
Terminated Phase 1 Interventional

CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease

NCT00611637
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
CMV pp65 Specific T Cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Jul 24, 2026, 12:46 AM EDT